drugset / Trial / NCT06716645

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

NCT06716645

Phase 4 Completed 244 enrolled HALEON
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.

Timeline

Start
2024-12-04
Primary completion
2025-02-14
Completion
2025-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 20 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject Doxylamine Small molecule 12.5 mg
Subject Guaifenesin Small molecule 400 mg Oral

Indications